# SpyGlass Pharma, Inc.: overview SGP · Nasdaq · CIK 1778922 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sgp.md) · [Financials](/companies/sgp/financials.md) · [Filings](/companies/sgp/filings.md) · [Insiders](/companies/sgp/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.96)](/filings/0001778922-26-000035.md) | [(3.81)](/filings/0001778922-26-000045.md) | [(0.69)](/filings/0001778922-26-000035.md) | [(0.59)](/filings/0001778922-26-000045.md) | | Free cash flow | $m | [(8.4)](/filings/0001778922-26-000035.md) | [(6.4) d](/filings/0001778922-26-000045.md) | [(14.2)](/filings/0001778922-26-000035.md) | [(16.8) d](/filings/0001778922-26-000045.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | | Revenue | $m | not reported | not reported | | Gross margin | % | not reported | not reported | | Operating margin | % | not reported | not reported | | Net margin | % | not reported | not reported | | Diluted EPS | $ per share | [(16.31)](/filings/0001778922-26-000020.md) | [(17.98)](/filings/0001778922-26-000020.md) | | Free cash flow | $m | [(24.0)](/filings/0001778922-26-000020.md) | [(33.5)](/filings/0001778922-26-000020.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sgp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $178.6m | 8,021,117 | | Unchanged | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $164.6m | 7,392,301 | | Unchanged | | [Sands Capital Alternatives, LLC](/funds/1846444.md) | 2026-06-30 | $55.7m | 2,500,012 | | Unchanged | | [SAMSARA BIOCAPITAL, LLC](/funds/1744967.md) | 2026-06-30 | $47.0m | 2,109,953 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.8m | 711,712 | | Added +566,973 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $14.9m | 670,000 | | Added +3,240 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $13.6m | 629,739 | | Added +52,630 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $12.2m | 550,000 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $11.3m | 507,257 | | Added +38,463 | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $11.0m | 493,076 | | Added +272,622 | ## Recent filings [All 92 filings](/companies/sgp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 20:10 ET | [8-K](/filings/0001778922-26-000052.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001778922-26-000052 | | 2026-10-01 | 12:15 ET | [8-K](/filings/0001778922-26-000049.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001778922-26-000049 | | 2026-08-06 | 20:37 ET | [10-Q](/filings/0001778922-26-000045.md) | Quarterly report, period 2026-06-30 | 0001778922-26-000045 | | 2026-08-06 | 20:16 ET | [8-K](/filings/0001778922-26-000044.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001778922-26-000044 | | 2026-05-14 | 20:30 ET | [10-Q](/filings/0001778922-26-000035.md) | Quarterly report, period 2026-03-31 | 0001778922-26-000035 | | 2026-05-14 | 20:15 ET | [8-K](/filings/0001778922-26-000033.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001778922-26-000033 | | 2026-03-26 | 21:23 ET | [10-K](/filings/0001778922-26-000020.md) | Annual report, period 2025-12-31 | 0001778922-26-000020 | | 2026-03-26 | 20:06 ET | [8-K](/filings/0001778922-26-000018.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001778922-26-000018 | | 2026-03-09 | 20:05 ET | [8-K](/filings/0001778922-26-000004.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001778922-26-000004 | | 2026-02-17 | 00:21 ET | [SCHEDULE 13D](/filings/0001346824-26-000061.md) | Ownership report, active investor | 0001346824-26-000061 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001778922-26-000020.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1778922 - Tickers: SGP - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.